✦ LIBER ✦

Budget Impact Analysis of Biosimilar Infliximab Treatment for Rheumatoid Arthritis in Six Central European Countries

✍ Scribed by Brodszky, V.; Péntek, M.; Baji, P.; Balogh, O.; V. Hevér, N.; Gulacsi, L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Budget impact analysis of biosimilar inf

✍ Brodszky, Valentin; Baji, Petra; Balogh, Orsolya; Péntek, Márta 📂 Article 📅 2014 🏛 Springer 🌐 French ⚖ 287 KB

Introduction of an Infliximab Biosimilar

✍ McCarthy, G.; Ebel Bitoun, C.; Guy, H. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Budget Impact Analysis of Biologic Drugs

✍ Ignatyeva, V.; Goryaynov, S.; Avxentyeva, M. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Impact of concomitant DMARD therapy on a

✍ Lars Erik Kristensen, Tore Saxne, Jan-Åke Nilsson… 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 355 KB

PMS45 Cost-Utility and Budget Impact Ana

✍ N. Maniadakis; D. Boumpas; G. Kourlaba; P. Christou; I. Anargiros; E. Smets; O P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Real-world effectiveness of abatacept fo

✍ Nüßlein, Hubert G; Alten, Rieke; Galeazzi, Mauro; Lorenz, Hanns-Martin; Boumpas, 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 315 KB